Goldman Sachs raises CSPC (01093. HK) target price to 13.5 yuan, buy rating

1
1
Favorite

Goldman Sachs raises CSPC (01093. HK) target price to 13.5 yuan, buy rating

AAFN2021-05-25

Goldman Sachs issued a report, raising CSPC's net profit forecast from 2021 to 2023 by 7.6%, 4.2%, and 5.9% respectively., including the valuation of innovative drugs from 111 billion yuan to 85.9 billion yuan to reflect the impact of new drug price cuts, but the valuation of generic drugs has been raised from 24 billion yuan to 52 billion yuan, because as more new generic drugs gain market share through volume procurement, the growth prospects of related businesses will improve. While considering the rising prices during the pandemic, API...

Web link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

风雪腊梅
·2021-05-25
???
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2138503001?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","is_english":false,"pubTime":"2021-05-25 09:56","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2138503001","market":"us","top_or_hot":-1,"title":"Goldman Sachs raises CSPC (01093. HK) target price to 13.5 yuan, buy rating","media":"AAFN","content":"<p><div>Goldman Sachs issued a report, raising CSPC's net profit forecast from 2021 to 2023 by 7.6%, 4.2%, and 5.9% respectively., including the valuation of innovative drugs from 111 billion yuan to 85.9 billion yuan to reflect the impact of new drug price cuts, but the valuation of generic drugs has been raised from 24 billion yuan to 52 billion yuan, because as more new generic drugs gain market share through volume procurement, the growth prospects of related businesses will improve. While considering the rising prices during the pandemic, API...</p><p><a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1100825&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web link</a></div></p>","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs raises CSPC (01093. HK) target price to 13.5 yuan, buy rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs raises CSPC (01093. HK) target price to 13.5 yuan, buy rating\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">AAFN</strong><span class=\"h-time small\">2021-05-25 09:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div>Goldman Sachs issued a report, raising CSPC's net profit forecast from 2021 to 2023 by 7.6%, 4.2%, and 5.9% respectively., including the valuation of innovative drugs from 111 billion yuan to 85.9 billion yuan to reflect the impact of new drug price cuts, but the valuation of generic drugs has been raised from 24 billion yuan to 52 billion yuan, because as more new generic drugs gain market share through volume procurement, the growth prospects of related businesses will improve. While considering the rising prices during the pandemic, API...</p><p><a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1100825&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web link</a></div></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1100825&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">AAFN</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1100825&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2138503001","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2138503001","pubTimestamp":1621907817,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"高盛发表报告，将石药集团  2021至2023年各年净利润预测分别上调7.6%、4.2%、5.9%，以分类加总估值法计，将目标价由12.5元提高至13.5元，评级「买入」，包括创新药估值由1,110亿元下调至859亿元，以反映新药降价的影响，不过仿制药估值就由240亿元上调至520亿元，因随着更多新的非专利药通过带量采购获得市场份额，令相关业务增长前景将得到改善。而考虑到疫情期间价格上涨，原料药估值由140亿元上调至230亿元。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01093":"石药集团"},"translate_title":"Goldman Sachs raised the target price of Shiyao (01093. HK) to 13.5 yuan rating \"buy\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"高盛发表报告，将石药集团  2021至2023年各年净利润预测分别上调7.6%、4.2%、5.9%，以分类加总估值法计，将目标价由12.5元提高至13.5元，评级「买入」，包括创新药估值由1,110亿元下调至859亿元，以反映新药降价的影响，不过仿制药估值就由240亿元上调至520亿元，因随着更多新的非专利药通过带量采购获得市场份额，令相关业务增长前景将得到改善。而考虑到疫情期间价格上涨，原料药估值由140亿元上调至230亿元。高盛指，石药第一季销售额为67亿元人民币，按年同比增长9.9%，略高於预期，主要因为降价後新产品的销售增长较快，而且肿瘤产品组合强劲。即使产品降价，但第一季的利润率明显扩张，毛利率按年扩张3.1个百分点至77%，预计全年的研发费用将达到34亿元，以支持加快临床进度。(ha/da)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":138128803,"gmtCreate":1621918917702,"gmtModify":1704364447822,"author":{"id":"3581155580868820","authorId":"3581155580868820","name":"风雪腊梅","avatar":"https://static.tigerbbs.com/6098bb5390cb75567a6e67bf6a793e29","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581155580868820","authorIdStr":"3581155580868820"},"htmlText":"???","listText":"???","text":"???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/138128803","repostId":2138503001,"repostType":2,"repost":{"id":"2138503001","kind":"news","pubTimestamp":1621907817,"share":"https://ttm.financial/m/news/2138503001?lang=&edition=fundamental","pubTime":"2021-05-25 09:56","market":"us","language":"zh","title":"高盛上调石药(01093.HK)目标价至13.5元  评级「买入」","url":"https://stock-news.laohu8.com/highlight/detail?id=2138503001","media":"AAFN","summary":"高盛发表报告，将石药集团  2021至2023年各年净利润预测分别上调7.6%、4.2%、5.9%，以分类加总估值法计，将目标价由12.5元提高至13.5元，评级「买入」，包括创新药估值由1,110亿元下调至859亿元，以反映新药降价的影响，不过仿制药估值就由240亿元上调至520亿元，因随着更多新的非专利药通过带量采购获得市场份额，令相关业务增长前景将得到改善。而考虑到疫情期间价格上涨，原料药估值由140亿元上调至230亿元。","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告，将<a href=\"https://laohu8.com/S/01093\">石药集团</a>  2021至2023年各年净利润预测分别上调7.6%、4.2%、5.9%，以分类加总估值法计，将目标价由12.5元提高至13.5元，评级「买入」，包括创新药估值由1,110亿元下调至859亿元，以反映新药降价的影响，不过仿制药估值就由240亿元上调至520亿元，因随着更多新的非专利药通过带量采购获得市场份额，令相关业务增长前景将得到改善。而考虑到疫情期间价格上涨，原料药估值由140亿元上调至230亿元。高盛指，石药第一季销售额为67亿元人民币，按年同比增长9.9%，略高於预期，主要因为降价後新产品的销售增长较快，而且肿瘤产品组合强劲。即使产品降价，但第一季的利润率明显扩张，毛利率按年扩张3.1个百分点至77%，预计全年的研发费用将达到34亿元，以支持加快临床进度。(ha/da)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛上调石药(01093.HK)目标价至13.5元  评级「买入」</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛上调石药(01093.HK)目标价至13.5元  评级「买入」\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-25 09:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1100825&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告，将石药集团  2021至2023年各年净利润预测分别上调7.6%、4.2%、5.9%，以分类加总估值法计，将目标价由12.5元提高至13.5元，评级「买入」，包括创新药估值由1,110亿元下调至859亿元，以反映新药降价的影响，不过仿制药估值就由240亿元上调至520亿元，因随着更多新的非专利药通过带量采购获得市场份额，令相关业务增长前景将得到改善。而考虑到疫情期间价格上涨，原料药...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1100825&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","relate_stocks":{"01093":"石药集团"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1100825&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2138503001","content_text":"高盛发表报告，将石药集团  2021至2023年各年净利润预测分别上调7.6%、4.2%、5.9%，以分类加总估值法计，将目标价由12.5元提高至13.5元，评级「买入」，包括创新药估值由1,110亿元下调至859亿元，以反映新药降价的影响，不过仿制药估值就由240亿元上调至520亿元，因随着更多新的非专利药通过带量采购获得市场份额，令相关业务增长前景将得到改善。而考虑到疫情期间价格上涨，原料药估值由140亿元上调至230亿元。高盛指，石药第一季销售额为67亿元人民币，按年同比增长9.9%，略高於预期，主要因为降价後新产品的销售增长较快，而且肿瘤产品组合强劲。即使产品降价，但第一季的利润率明显扩张，毛利率按年扩张3.1个百分点至77%，预计全年的研发费用将达到34亿元，以支持加快临床进度。(ha/da)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}